Mil 25

Manufactured by R&D Systems

The MIL-25 is a laboratory instrument designed for cell culture applications. It is capable of providing precise temperature and humidity control for optimal cell growth and maintenance.

Automatically generated - may contain errors

Lab products found in correlation

Mil 7, by R&D Systems (2 mentions) Mil 33, by R&D Systems (2 mentions) Plzf 9e12, by BioLegend (1 mentions) Fluorochrome conjugated streptavidin, by BD (1 mentions) Gata3 l50 823, by BD (1 mentions) Recombinant mil 2, by R&D Systems (1 mentions) Ra3 6b2, by BD (1 mentions) Celltiter glo luminescent cell viability assay, by Promega (1 mentions) Mil 2, by R&D Systems (1 mentions) Ovalbumin (ova), by R&D Systems (1 mentions) Ovalbumin (ova), by Merck Group (1 mentions)

3 protocols using mil 25

Multiparametric Flow Cytometry Analysis of Mouse Immune Cell Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols

For flow-cytometric analyses, mAbs specific for mouse CD3ε (145-2C11), CD8α (53–6.7), CD19 (1D3), B220 (RA3-6B2), NK1.1 (PK136), CD11b (M1/70), CD11c (HL3), Gr-1 (RB6-8C5), TER119 (TER119), CD45.1 (A20), CD45.2 (2F1), Sca-1 (E13-161.7), CD25 (PC61), Thy1.2 (53–2.1), Flt3 (A2F10), α4β7 (DATK32), KLRG1 (2F1), CCR9 (CW-1.2), CD31 (MEC13.3), GATA3 (L50-823), T-bet (O4-46), RORγt (Q31-378), IFN-γ (XMG1.2), IL-17A (TC11-18H10), and fluorochrome-conjugated streptavidin were purchased from BD. mAbs against mouse Notch1 (HMN1-12), Notch2 (HMN2-35), CD4 (GK1.5), PDGFRα (ATA5), gp38 (8.1.1), and PLZF (9E12) were purchased from BioLegend. mAbs against c-Kit (2B8), FcεRIα (MAR-1), IL-7Rα (A7R34), and IL-13 (eBio13A) were purchased from eBioscience. Anti-T1/ST2 (DJ8) was purchased from MD Biosciences. mAb against mouse CD16/CD32 (2.4G2) was purified from hybridoma culture supernatants in our laboratory.
Recombinant mIL-2, mIL-7, mIL-25, mIL-33, and mTSLP were purchased from R&D Systems. A STAT5 inhibitor (CAS 285986–31-4) was purchased from Calbiochem, and Dox was purchased from Clontech.

Koga S., Hozumi K., Hirano K.I., Yazawa M., Terooatea T., Minoda A., Nagasawa T., Koyasu S, & Moro K. (2018). Peripheral PDGFRα+gp38+ mesenchymal cells support the differentiation of fetal liver–derived ILC2. The Journal of Experimental Medicine, 215(6), 1609-1626.

+ Open protocol

+ Expand

ILC2 Cell Proliferation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Two thousand sorted stomach or SI ILC2s (CD45 + CD3 -CD19 -TCRb -CD127 + Sca1 + KLRG1 + IL-33R + cells) were cultured in the presence of recombinant mIL-2, mIL-7, mIL-25 or mIL-33 (10 ng/ml each; R&D systems) for 6 days, and cell proliferation were determined using the CellTiter-GloÒ Luminescent Cell Viability Assay (Promega) and a luminometer (Promega). The baseline was established from two thousand cells of sorted stomach or SI ILC2s without culture or stimulation. Serial dilutions of fresh splenocytes were used to obtain a standard curve and cell numbers were calculated following the formula based on this standard curve.

Satoh-Takayama N., Kato T., Motomura Y., Kageyama T., Taguchi-Atarashi N., Kinoshita-Daitoku R., Kuroda E., Di Santo J.P., Mimuro H., Moro K, & Ohno H. (2020). Bacteria-Induced Group 2 Innate Lymphoid Cells in the Stomach Provide Immune Protection through Induction of IgA. Immunity, 52(4).

+ Open protocol

+ Expand

Murine Model of Allergen-Induced Asthma

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were divided into 3 groups, including a group serially challenged with OVA (a “classical” allergen-induced asthma model) [14 (link),17 (link)], a group challenged with saline as a negative control and a group serially challenged with IL-25. Briefly, OVA-challenged group were first sensitized by intraperitoneal injection of OVA (Sigma-Aldrich, Beijing, China, 100 μg emulsionised in Al[OH]3/dose) on days 0 and 12. Then 50 μg of OVA (OVA50) in 50 μL saline/dose were further administered to these mice daily by nasal instillation from days 18 to 23. IL-25 challenged group were not sensitized to OVA on days 0 and 12, but suffered daily nasal instillation with recombinant mouse IL-25 (mIL-25, R&D Systems, 2 μg in 50 uL saline) from days 18 to 23 [14 (link),18 (link)]. Subsequently, these mice were further challenged intranasally either with OVA (OVA50 group) or with IL-25 (IL-25 group) every 2 days for a further 30 days. 5 mice in each group were observed for a further 17 days after stopping the challenges. Saline negative group was intraperitoneally injected with the same amount of Al[OH]3 on days 0 and 12, then nasally administered with saline at time points corresponding to those in the other groups.

Yao X., Wang W., Li Y., Huang P., Zhang Q., Wang J., Wang W., Lv Z., An Y., Qin J., Corrigan C.J., Huang K., Sun Y, & Ying S. (2015). IL-25 induces airways angiogenesis and expression of multiple angiogenic factors in a murine asthma model. Respiratory Research, 16(1), 39.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!